Industry Themes

MP Group: Outlook on Global Medical Communications Outsourcing

Pleasure to share with you our Outlook on ‘Global Medical Communications Outsourcing’. Medical communications is becoming an integral part of drug development and commercialization strategy, owing to the pursuit of innovative and complex therapies, articulation of medical and economic benefits and adopting a patient-centric approach. As a result, the medical communications outsourcing market, from a current base of ~$2B in 2023, is expected to reach ~$8B by 2026, growing at a CAGR of 18%. The evolution of technology and omnichannel…

Continue Reading

MP Group: Outlook on Growth of the US biosimilars market – Key trends and opportunities

Pleasure to share our Outlook on Growth of the US biosimilars market – Key trends and opportunities. Historically, the US biosimilars market has posed several challenges restricting its penetration. Ambiguous regulatory guidelines contributing to high cost and timelines for development, patent dance causing uncertainties with launch timelines and barriers posed by the innovators limiting the market penetration – all of these led to the biosimilars market only dominated by the innovator companies. However, over the last 3-5 years, the landscape…

Continue Reading

MP Group: Trends in the Bio-IT Services Industry

We are pleased to share with you our latest industry insights report titled Trends in the Bio-IT Services Industry. This report is based on insights derived from conversations with 50 CEOs of small to mid-sized companies providing life sciences-specific IT services across the R&D value chain. Digital transformation has become a top priority across the life sciences leadership, fuelling the growth of Bio-IT solutions companies at a remarkable pace. Over the last few years, the Bio-IT services companies are witnessing…

Continue Reading

MP Group: Outlook on Specialized Chemistry Outsourcing

It is our pleasure to share with you our Outlook on ‘Specialized Chemistry Outsourcing’ Complex modalities like ADCs, OligonucleoTIDES, PepTIDES (TIDES), etc. are becoming a key part of the biopharma pipeline, with applications across a wide range of indications. However, the infancy of ADC and the TIDES therapeutics pose several development and manufacturing challenges, from technology and process development to manufacturing and fill-finish. Therefore, biopharma is turning to outsourcing partners to offer strategic support to address these challenges. CDMOs, in…

Continue Reading

MP Group: Outlook on the CROs for the new-age Biopharma

It is our pleasure to share with you our outlook on the ‘CROs for the new-age Biopharma’. The drug development landscape is rapidly shifting towards complex targets and new drug modalities, with growth in cell & gene therapy and ADC pipeline now outpacing traditional small molecule drug candidates. As a result, the Biopharma cos are seeking CROs that can become an extension of their scientific think-tank, providing intellectual inputs and cutting edge research insights. It will be critical for CROs…

Continue Reading

MP Group: Outlook on the mRNA Bio-CDMOs – A key catalyst for the evolution of mRNA therapeutics

It is our pleasure to share with you our outlook on the ‘mRNA Bio-CDMOs – A key catalyst for the evolution of mRNA therapeutics.’ mRNA therapeutics played a pivotal role in the pandemic management thereby generating unparalleled interests (and investments) across the biopharma as well as investor groups. mRNA Covid-19 vaccines have paved the pathway for regulatory approvals. As a result, the clinical pipeline of mRNA therapeutics has expanded several fold across wide range of indications beyond infectious disease such…

Continue Reading

MP Group – A Global Outlook of HEOR (Health Economics and Outcomes Research) Services

We are glad to share our global outlook on Health Economics and Outcomes Research (HEOR) services. The field of Health Economics and Outcomes Research (HEOR) has undergone a significant transformation, shifting from a supportive role to a prominent position in the launch of drug products in the past decade. With the rising research and development costs, innovative therapeutic approaches and government initiative to curtail healthcare expenditures, we anticipate a persistent rise in the demand for HEOR services to demonstrate the…

Continue Reading

MP Group: Outlook on ‘Promise of Digital Health-2022’

We are glad to present our outlook on ‘Promise of Digital Health-2022’. The presentation outlines the potential of digital health in transforming healthcare delivery and associated opportunities for the biopharma industry. Digital health solutions are increasingly demonstrating its value towards a number of facets of healthcare delivery - from patient-centric apps for personalised content, guidance and medication adherence, sensors/wearables for real time monitoring, and remote access to health systems like teleconsultations, all of which aimed towards improved healthcare outcomes. Beyond improved…

Continue Reading

MP Group: Outlook on ‘Artificial Intelligence in Target and Biomarker Discovery-2022′

We are glad to present our outlook on ‘Artificial Intelligence in Target and Biomarker Discovery-2022’. The attached presentation outlines how AI can better elucidate disease biology and assist with building a robust hypothesis for target and biomarker identification. Most clinical trials fail because of poor safety and efficacy resultant from a lack of holistic disease understanding. The traditional approaches are usually unidimensional and fail to account for the complex nature of biology. While we are observing an explosion of healthcare data,…

Continue Reading

Outlook on AI and medical writing

We are glad to present our outlook on ‘AI and medical writing’ that gives an overall perspective on the technological advancements in the medical writing industry. Medical writing is expected to be a $5B+ market with a ~10% CAGR in the next 5 years. However, the industry faces the challenge of high attrition rates and lack of resources. Inefficiencies are further fueled by limited use of automation to reuse content between different regulatory documents and publications as well as limited…

Continue Reading
Close Menu